Entinostat
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkin's Lymphoma
Conditions
Hodgkin's Lymphoma
Trial Timeline
Apr 13, 2009 → Feb 8, 2013
NCT ID
NCT00866333About Entinostat
Entinostat is a phase 2 stage product being developed by Syndax Pharmaceuticals for Hodgkin's Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00866333. Target conditions include Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03361800 | Phase 1 | Terminated |
| NCT03192111 | Phase 1 | Completed |
| NCT02922933 | Phase 1 | Completed |
| NCT02922946 | Phase 1 | Completed |
| NCT00866333 | Phase 2 | Terminated |
Competing Products
20 competing products in Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 77 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |